Cases
Search U.S. court opinions (CourtListener / Free Law Project), or resolve a reporter citation to its case via the Caselaw Access Project. Facts only — name, court, date, status, citation count. Never a holding-summary.
4 opinions for “Federal Trade Commission v. Quincy Bioscience Holding Company, Inc.”
OPINION & ORDER LOUIS L. STANTON, U.S.D.J. Plaintiffs Federal Trade Commission (“FTC”) and the People of the State of New York, by Eric T. Schneiderman, Attorney General of the State of New York, seek injunctive and other equitable relief for alleged violations of federal and state deceptive advertising laws. All defendants move to dismiss the complaint for failure to
Fed. Trade Comm'n v. Quincy Bioscience Holding Co.public domain
LOUIS L. STANTON, U.S.D.J. Plaintiffs Federal Trade Commission ("FTC") and the People of the State of New York brought this action alleging violations of the Federal Trade Commission Act and New York law for deceptive advertising of a dietary supplement ("Prevagen") purporting to improve one's memory. Defendants move to dismiss the complaint for failure to state a claim upon which relief can be granted and for lack of personal juris
MEMORANDUM OPINION BERYL A. HOWELL, United States District Judge The plaintiff, Pharmaceutical Research and Manufacturers of America (“PhRMA”), a trade association which “represents the country’s leading biophar-maceutical researchers and biotechnology companies,” see Compl. ¶¶ 9-10, ECF No. 1, seeks to set aside a Final
In re Prevagen Prods. Mktg. & Sales Practices Litig.public domain
SARAH S. VANCE, Chair Before the Panel:* Defendants Quincy Bioscience Holding Company, Inc., Quincy Bioscience, LLC, Prevagen, Inc., Quincy Bioscience Manufacturing, LLC, Mark Underwood, and Michael Beaman move to centralize four actions in the Southern District of New York. The actions, which are listed on the attached Schedule A, are pending in the Northern District of California, the